期刊文献+

间日疟原虫多表位疫苗基因的表达、纯化与初步鉴定 被引量:3

Expression,purification and initial identification of the multi-epitope gene of Plasmodium vivax in Pichia pastoris
原文传递
导出
摘要 目的构建和筛选间日疟原虫多表位疫苗基因高拷贝Pichia pastoris菌株,研究多表位疫苗基因在酵母菌中的表达,纯化目的产物,为进一步的多表位肽免疫原性研究奠定基础。方法根据文献报道筛选间日疟原虫有效保护性抗原表位,人工合成多表位基因PvDBW,经EcoRⅠ和NotⅠ双酶切构建酵母表达载体pPIC9K-PvDBW,转化大肠埃希菌ToP10;鉴定后转化P.pastoris GS115,构建酵母表达菌株;通过G418压力筛选筛出目的基因高拷贝克隆,用甲醇诱导多表位肽基因表达,分别以RT-PCR和Western blot进行鉴定,用50%饱和硫酸铵沉淀和分子筛凝胶层析分离、纯化目的产物。结果重组质粒用EcoRⅠ和NotⅠ双酶切后可得到786 bp DNA片段;经G418压力筛选筛出两个高拷贝菌株,以α-Factor和3′AOX1为引物、重组菌基因组DNA为模板,PCR扩增出约960 bp的目的片段;SDS-PAGE显示,在GS115细胞内多表位肽呈分泌性表达,表达量为80 mg/L;分离、纯化后,纯度达90%以上;Western blot检测显示表达的多表位肽可被间日疟病人血清识别。结论间日疟原虫多期多阶段多表位疫苗基因在酵母菌中表达成功。 Objective To express the multi epitope gene(PvDBW) of Plasmodium vivax in Pichia pastoris. Methods A multi epitope gene(PvDBW) of P. vivax was designed, synthesized, cloned into expression vector pPICgK, and expressed in P. pastoris GS115 by induced with 1% methanol. The expressed product was purified, identified with RT- PCR and Western blot. Results A 786 bp multi-epitope gene(PvDBW) of P. vivax was designed and synthesized, and recombinant plasmid pPIC9K/PvDBW was constructed. SDS-PAGE showed that the gene was expressed in form of soluble molecule in supernatant of induced pPIC9K/PvDBW/GS115 and the rate of the interesting peptide was 80 mg/L. The peptide was specifically recognized by patients' sera infected with P. vivax. The purity of expressed product reached above 90% after purified. Conclusion Recombinant plasmid pPICgK/PvDBW is successfully constructed and the multiepitope peptide of P. vivax is expressed in P. pastoris in supernatant in the form of soluble molecule. These results set up a foundation for the further experiments in animals.
出处 《中国病原生物学杂志》 CSCD 2009年第1期32-35,共4页 Journal of Pathogen Biology
基金 国家自然科学基金项目(No.30271164) 军队"十五"指令性课题
关键词 疟原虫 间日 多表位疫苗基因 毕赤巴斯德酵母 表达 Plasmodium vivax multi-epitope gene Pichia pastoris expression
  • 相关文献

参考文献10

  • 1Pillips EJ, Keystone JS, Kain KC. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium viva:r malaria acquired in Guyana. South America[J]. Clin Infect Dis, 1996,23:171--173.
  • 2Kocken CHM, Dubbeld MA, Vander Wel A, et al. High-level expression of Plasmodium vivax apical membrane antigen ( AMA-1) in Pichia pastoris strong immunogenicity in Macaca mulatla immunized with P. vivax AMA-1 and adjuvant SBAS2[J]. Infect Immunol, 1999,67:43--49.
  • 3Nardin EH, Oliveira GA, Calvo-Calle JM, et al. The use of multiple antigen peptides in the analysis.and induction of protective immune responses against infectious diseases[J]. Ade Immun, 1995,60: 105-- 149.
  • 4Rogers WO, Gowda K, Hoffman SL. Construction and immunogenicity of DNAa vaccine plasmid encoding four Plasmodium viva:c candidate vaccine antigens[J]. Vaccine, 1999,17 : 3136 - 3144.
  • 5金冬雁,黎孟枫,侯云德,等.译.J.萨姆布鲁克,D.W.拉塞尔.分子克隆实验指南[M],第2版.北京:科学出版社,1992.343-355.
  • 6Bojang KA, Milligan PJM, Pinder M, et al. Efficacyof RTS,S/ AS02 malaria vaccine against Plasrnodiurn falciparurn infection in semi immune adult men in the Gambia: a randomised trial[J]. Lancent, 2001,358(9297) : 1927--1934.
  • 7Gretchen V. A complex new vaccine show promise[J]. Science, 2004,306(5696) :587-589.
  • 8del Guercio MF, Alexander J, Kubo RT,et al. Potent immunogenic short linear peptide construts composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo[J]. Vaccine, 1997,15:441-448.
  • 9Stowers AW, Cioce V, Shimp RL, et al. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial[J]. Infect Immun, 2001,69 (3):1536-1546.
  • 10Brady CP, Shimp RL, Miles AP, et al. High-level production and purification of P30P2MSP1 ( 19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris[J]. Protein Expr Purif, 2001,23(3) :468--475.

共引文献9

同被引文献39

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部